John M. Davis
Impact in
- Biological Psychiatry top 0.05%
- Tryptophan and brain disorders
- Psychiatry and Mental health top 0.01%
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
Papers in
-
- Schizophrenia research and treatment 176
- Bipolar Disorder and Treatment 55
- Co-authors
- Stefan Leucht (78 shared papers)Werner Kissling (21 shared papers)Rolf R. Engel (13 shared papers)Myrto Samara (18 shared papers)Stephan Heres (12 shared papers)Nancy Chen (6 shared papers)Joseph R. Hibbeln (28 shared papers)Georgia Salanti (17 shared papers)
- Journals
- American Journal of Psychiatry (22 papers)Schizophrenia Research (21 papers)Schizophrenia Bulletin (20 papers)Journal of Clinical Psychopharmacology (18 papers)Biological Psychiatry (18 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
John M. Davis
648 papers receiving 37.7k citations
John M. Davis's Hit Papers
Peers
Comparison fields: 5 of 224
- Biological Psychiatry 2.5k
- Psychiatry and Mental health 15.0k
- Behavioral Neuroscience 1.2k
- Rehabilitation 1.7k
- Cellular and Molecular Neuroscience 4.7k
Countries citing papers authored by John M. Davis
This map shows the geographic impact of John M. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Davis more than expected).
Fields of papers citing papers by John M. Davis
This network shows the impact of papers produced by John M. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Davis. The network helps show where John M. Davis may publish in the future.
Co-authors
The 25 scholars most cited alongside John M. Davis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 681 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Hit paper breakdown → | 2013 | 1936 |
| 2 | Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Hit paper breakdown → | 2008 | 1491 |
| 3 | Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis Hit paper breakdown → | 2019 | 1016 |
| 4 | Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study Hit paper breakdown → | 2007 | 794 |
| 5 | A Meta-analysis of the Efficacy of Second-Generation Antipsychotics Hit paper breakdown → | 2003 | 767 |
| 6 | Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis Hit paper breakdown → | 2012 | 652 |
| 7 | The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis Hit paper breakdown → | 1997 | 650 |
| 8 | The Altman Self-Rating Mania Scale Hit paper breakdown → | 1997 | 644 |
| 9 | A decrease of reelin expression as a putative vulnerability factor in schizophrenia Hit paper breakdown → | 1998 | 627 |
| 10 | Omega-3 Fatty Acids: Evidence Basis for Treatment and Future Research in Psychiatry Hit paper breakdown → | 2006 | 571 |
| 11 | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis Hit paper breakdown → | 2010 | 528 |
| 12 | Dose Equivalents for Antipsychotic Drugs: The DDD Method: Table 1. Hit paper breakdown → | 2016 | 517 |
| 13 | 1995 | 422 | |
| 14 | Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis Hit paper breakdown → | 2013 | 403 |
| 15 | 2009 | 401 | |
| 16 | 1976 | 385 | |
| 17 | 2008 | 384 | |
| 18 | 2008 | 377 | |
| 19 | Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors Hit paper breakdown → | 2017 | 370 |
| 20 | Guidelines for the use of cell lines in biomedical research Hit paper breakdown → | 2014 | 356 |
About John M. Davis
John M. Davis is a scholar working on Psychiatry and Mental health, Molecular Biology, Cellular and Molecular Neuroscience, Physiology and Pharmacology, having authored 681 papers that have together received 40.4k indexed citations. Recurring topics across this work include Schizophrenia research and treatment (176 papers), Bipolar Disorder and Treatment (55 papers), Neurotransmitter Receptor Influence on Behavior (48 papers), Treatment of Major Depression (40 papers), Tryptophan and brain disorders (35 papers), Exercise and Physiological Responses (33 papers), Neuroscience and Neuropharmacology Research (27 papers) and Muscle metabolism and nutrition (25 papers). The work is most often cited by research in Biological Psychiatry (2.5k citations), Psychiatry and Mental health (15.0k citations), Behavioral Neuroscience (1.2k citations), Rehabilitation (1.7k citations) and Cellular and Molecular Neuroscience (4.7k citations). John M. Davis has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Stefan Leucht, Werner Kissling, Rolf R. Engel, Myrto Samara, Stephan Heres, Nancy Chen, Joseph R. Hibbeln, Georgia Salanti, Ghanshyam N. Pandey and E. Angela Murphy. Their work appears in journals such as American Journal of Psychiatry, Schizophrenia Research, Schizophrenia Bulletin, Journal of Clinical Psychopharmacology and Biological Psychiatry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.